Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syncom Formulation (India)BOM:524470 +0.51%87 Pretax Margin % is 24.89% as of Mar. 2026, which is 108% above its 10-year median of 11.98. GuruFocus rates BOM:524470 with a GF Score™ of 87/100 and a GF Value™ of ₹19.99 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 961 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 82.1% on this metric.
The historical rank and industry rank for Syncom Formulation (India)'s Pretax Margin % or its related term are showing as below:
BOM:524470'
s Pretax Margin % Range Over the Past 10 Years
Min: 6.97 Med: 11.98 Max: 20.67
Current: 20.67
BOM:524470's Pretax Margin % is ranked better than 82.1% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs BOM:524470: 20.67
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Syncom Formulation (India) Pretax Margin % Related Terms
Syncom Formulation (India) Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524470 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syncom Formulation (India) (BOM:524470) has a Pretax Margin % of 24.89% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Syncom Formulation (India) and its competitors. This is 108% above median its historical median of 11.98. Over the past decade, Syncom Formulation (India)'s Pretax Margin % has ranged from 6.97 to 20.67. According to the industry distribution chart, Syncom Formulation (India) ranks #172 out of 961 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Syncom Formulation (India)'s Pretax Margin % too high?
Syncom Formulation (India)'s current Pretax Margin % of 24.89% is 108% above median its 10-year median of 11.98. Over the past 10 years, this metric has ranged from a low of 6.97 to a high of 20.67. The Drug Manufacturers industry median Pretax Margin % is 7.28. Syncom Formulation (India)'s value of 24.89% is 241.9% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #172 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Syncom Formulation (India) has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #172 out of 961 companies for Pretax Margin %. This places Syncom Formulation (India) in the top 18% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Syncom Formulation (India)'s value of 24.89% is 241.9% above this benchmark. Historically, Syncom Formulation (India)'s own Pretax Margin % has ranged from 6.97 to 20.67 over the past decade. While the company's 10-year median is 11.98 vs. the industry median of 7.28, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current Pretax Margin % of 24.89% is 241.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Pretax Margin % is 24.89%, which is 108% above median its own 10-year median of 11.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹19.99, compared to a current price of ₹13.83 — trading 30.8% below its estimated fair value. The current Pretax Margin % is 24.89%, which is 108% above median its 10-year median of 11.98 and 241.9% above the Drug Manufacturers industry median of 7.28. Syncom Formulation (India)'s overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Pretax Margin % is 24.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹13.83 is trading 30.8% below its estimated GF Value™ of ₹19.99.
GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.
Key valuation signals for BOM:524470:
Pretax Margin %: 24.89% (108% above median its 10-year median of 11.98)
GF Value™: ₹19.99 vs. price of ₹13.83 (30.8% below fair value)
Industry Position: 241.9% above the Drug Manufacturers median (#172 of 961)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
87GF Score
Get the complete analysis for BOM:524470
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
